CAChantal Attard

Chantal Attard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chantal Attard has a total of 160 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Impact of ABO and RhD Blood Groups on Laboratory Parameters in Children

    by Gemma L. Crighton, Vicky Karlaftis, Chantal Attard, Stephen Hearps, Mary Comande, Janet Burgess, Paul Monagle

    Introduction: Developmental differences exist that impact laboratory reference intervals in children. Variances exist in ABO antigen expression and isohaemagglutinins through childhood. The impact of ABO and RhD blood group on laboratory parameters in children is unknown. Methods: The Harmonising Age Pathology Parameters in (HAPPI) Kids study is a prospective, cross‐sectional study, aiming to establish normative data for age‐appropriate reference intervals for laboratory parameters in healthy children. This study explores blood group‐related differences in laboratory parameters. Results: 2012 children had blood group testing. Haemoglobin was higher in group B compared with A (median difference 3.56 g/L [0.98–6.14]) ( p = 0.01) and red cell count (RCC) was higher in B compared with group A (0.23 × 10 12 /L [0.10–0.35]) ( p < 0.001) and O (0.19 × 10 12 /L [0.07–0.32]) ( p = 0.003). Haemoglobin and RCC were higher in B compared with non‐B. Group O had statistically lower Factor VIII levels than A (−0.40 IU/mL [−0.59 to −0.20]) ( p < 0.001), AB (−0.55 IU/mL [−0.73 to −0.36]) ( p < 0.001) and B (−0.45 [−0.81 to −0.10]) ( p = 0.027). VWF:Ag levels were lower in group O than A (−0.22 U/mL [−0.39 to −0.05]) ( p = 0.023) and B (−0.34 U/mL [−0.59 to −0.08]) ( p = 0.02). VWF:RCo was lower in group O than A (−0.34 U/mL [−0.50 to −0.17]) ( p < 0.001). Group O compared with non‐O had longer APTTs, lower FVIII and VWF parameters. No difference was found between RhD blood group and any parameter. Conclusion: This is the first study to explore whether ABO and RhD blood group impact routine laboratory parameters in children. Further studies are required to confirm the blood group‐related associations found and understand if ABO blood group impacts paediatric disease pathogenesis.

  • Anesthesia as a Partner in Public Health: Enabling National Pediatric SARS-CoV-2 Serosurveillance in Australia

    by Archana Koirala, Chantal Attard, Justin Skowno

    Anesthetic departments played a critical role in Australia’s COVID-19 response by facilitating the collection of residual blood samples from children undergoing elective procedures. Through a partnership with the Pediatric Active Enhanced Disease Surveillance network, this approach enabled three national SARS-CoV-2 serosurveys between 2020 and 2023. It provided an ethical, feasible, and nationally representative method for assessing infection- and vaccine-derived immunity in children, a population in whom routine blood sampling is difficult and from whom residual blood samples are not commonly available. The resulting data informed COVID-19 vaccination policy, improved understanding of infection burden and immunity, and contributed to broader public health decision-making. This experience demonstrates how anesthetic departments can extend their impact beyond perioperative care, serving as essential partners in public health surveillance and research.

  • Age-related Global Coagulation Changes: From Neonate to Old Age

    by Vincent Lu, Chantal Attard, Vasiliki Karlaftis, Tengyi Cai, Mani Suleiman, Ilaria De Simone, Dana Huskens, Bas De Laat, Denise Jackson, Catherine Itsiopoulos, et al.

    Global coagulation assays provide a comprehensive assessment of clotting and fibrinolytic dynamics and have shown potential in predicting bleeding and thrombotic risk. Successful clinical implementation, however, requires understanding of normal age-specific changes, which remains limited. This study aims to evaluate age- and sex-related differences in global coagulation assays from neonates to older adults. A total of 546 citrated plasma samples from 380 healthy pediatric participants (0 to < 18 years) and 166 adults (20–79 years, without known cardiovascular risk factors or medications affecting coagulation) were tested for thrombin generation (CAT-TG), modified overall hemostatic potential (mOHP), and plasmin generation (PG). This study demonstrated that hemostatic capacity was lowest at birth and increased rapidly throughout early childhood, with endogenous thrombin and plasmin potentials peaking in the fourth decade of life. Fibrin generation continued to rise, peaking in the sixth decade, accompanied by a decline in fibrinolytic capacity. Sex differences showed a hypercoagulable shift in females beginning at puberty, peaking during the reproductive years. These sex differences attenuated post-menopause, reflecting the convergence of cardiovascular risk in older age. These findings provide essential normative data to support age- and sex-adjusted interpretation of global coagulation assays. Overall, the most pronounced hemostatic changes occur in early life, consistent with developmental hemostasis. The midlife peak in procoagulant parameters and the decline in fibrinolytic capacity highlight progressive hemostatic changes associated with aging. While sex-related differences underscore the role of endogenous hormones in modulating coagulation, longitudinal studies in healthy and at-risk individuals are warranted to clarify trajectories and inform personalized interventions.

  • Platelets in Children: Physiological Function, Developmental Regulation, and Clinical Significance in Disease States.

    by Natasha Letunica, Paul Monagle, Chantal Attard

    Platelets play a fundamental role in hemostasis; however, their phenotype, reactivity, and function vary across the pediatric age spectrum. While developmental differences in plasma coagulation proteins have been well-characterized in children, differences in platelet biology remain poorly understood, with most studies focused on neonates. Consequently, the understanding of normal platelet phenotype and function in healthy children remains limited, making it difficult to interpret platelet changes in the context of disease. Platelet phenotype evolves from birth through adolescence, with ongoing changes in receptor expression and granule content. Functional responses also change with age, with neonatal platelets being hyporeactive compared with adult platelets, whereas platelets from older children may demonstrate increased responsiveness to common agonists. These developmental differences are increasingly recognized as clinically relevant across a range of pediatric disease states. However, key knowledge gaps remain in age-specific reference ranges and the translation of platelet biology into clinical practice. This review summarizes the current evidence on developmental differences in platelet production, phenotype, and reactivity from birth to adolescence and examines their clinical significance in pediatric disease states.

  • Open Access

    The in vitro anticoagulant effect of abelacimab in healthy children

    by Natasha Letunica, Simon Collett, Vasiliki Karlaftis, Yasser Khder, Debra Freedholm, Paul Monagle, Chantal Attard


  • Commercialisation Pathways for Academic Researchers

    by Chantal Attard

    This workshop explores how academic researchers can translate discoveries through commercialisation pathways while maintaining scholarly rigour and ethical clarity. It provides a strategically grounded introduction to licensing, partnerships, spin-outs, and related translational decisions for researchers seeking broader research impact.

  • The in vitro anticoagulant effect of milvexian in healthy neonates and children

    by Natasha Letunica, Vasiliki Karlaftis, Paul Monagle, Hernando Patino, Madhu Chintala, Chantal Attard


  • Open Access

    Hemostatic Outcome Definitions in Pediatric Extracorporeal Membrane Oxygenation: Challenges in Cohorts From Rotterdam (2019–2023) and Melbourne (2016–2022)

    by Joppe Drop, Suelyn BBiomedSciAdvHons Van Den Helm, Natasha Bsc Letunica, Enno Wildschut, Matthijs de Hoog, Willem de Boode, Rebecca Barton, Hui Ping Yaw, Fiona Newall, Stephen Horton, et al.

    OBJECTIVES: To determine if a priori standardization of outcome hemostatic definitions alone was adequate to enable useful comparison between two cohorts of pediatric extracorporeal membrane oxygenation (ECMO) patients, managed according to local practice and protocol. DESIGN: Comparison of two separate prospective cohort studies performed at different centers with standardized outcome definitions agreed upon a priori. SETTING: General and cardiac PICUs at the Royal Children’s Hospital (RCH) in Melbourne, Australia, and the Sophia Children’s Hospital (SCH) in Rotterdam, The Netherlands. PATIENTS: Children (0–18 yr old) undergoing ECMO. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Although outcome definitions were standardized a priori, the interpretation of surgical interventions varied. The SCH study included 47 ECMO runs (September 2019 to April 2023), and the RCH study included 97 ECMO runs (September 2016 to Jan 2022). Significant differences in patient populations were noted. RCH patients biased toward frequent cardiac ECMO indications, central cannulation, and cardiopulmonary bypass before ECMO. The frequency of outcome ascertainment was not standardized. CONCLUSIONS: This international comparison shows that standardizing hemostatic outcome definitions alone is insufficient for sensible comparison. Uniform interpretation of definitions, consistent frequency of outcome ascertainment, and stratification based on patient populations and ECMO practices are required. Our results highlight the granularity of detail needed for cross-center comparison of hemostatic outcomes in pediatric ECMO. Further work is needed as we move toward potential multicenter trials of pediatric ECMO.


  • Blood Collection Processing and Handling for Plasma and Serum Proteomics

    by Conor McCafferty, Natasha Letunica, Ella Swaney, Cai Tengyi, Paul Monagle, Vera Ignjatovic, Chantal Attard

    The plasma and serum proteome has enormous potential as a tool for understanding the health of a number of physiological systems. Despite this potential, the use of plasma and serum proteomics clinically and for research is limited, and there are no strict guidelines on how samples should be collected and prepared for proteomic analysis. Given the sensitivity of proteomic analysis, there are a number of pre-analytical variables that should be considered and determined prior to undertaking proteomics-based methodologies. In this chapter, we provide an example of a blood processing protocol and highlight major considerations for pre-analytical variables involving the collection, processing, and handling of blood samples for plasma and serum proteomics. We provide comprehensive notes on aspects of the protocol that must be considered before commencing sample collections for a proteomic study as well as a thorough checklist to be used when designing new proteomic studies. Key words Sample collection Blood handling Method development Pre-analytical variables


  • Proteomic Applications and Considerations: From Research to Patient Care

    by Natasha Letunica, Conor McCafferty, Ella Swaney, Tengyi Cai, Paul Monagle, Vera Ignjatovic, Chantal Attard

    Despite technological advancements in the field of proteomics, the rate at which serum and plasma biomarkers identified using proteomic approaches are translated into clinical use remains extremely low. In this chapter, we describe recent technological advancements and analytical strategies in proteomic methods. We also describe the progress of proteomic blood-based biomarkers to date and discuss what the future of proteomics might entail with the use of multi-omic approaches and implementing machine learning on large proteomic datasets. Lastly, we provide several key considerations for biomarker studies, ranging from sample type to the use of reference samples, in order to achieve progress from bench to bedside, ultimately improving patient diagnosis, disease, and/or therapeutic monitoring and care. Key words Proteomics Biomarker Plasma Serum Clinical utility